Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$0.43.

  • Relay Therapeutics' EPS (Basic) rose 3174.6% to -$0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.72, marking a year-over-year increase of 3409.96%. This contributed to the annual value of -$2.36 for FY2024, which is 1527.32% up from last year.
  • As of Q3 2025, Relay Therapeutics' EPS (Basic) stood at -$0.43, which was up 3174.6% from -$0.41 recorded in Q2 2025.
  • Relay Therapeutics' 5-year EPS (Basic) high stood at -$0.41 for Q2 2025, and its period low was -$2.1 during Q2 2021.
  • Over the past 5 years, Relay Therapeutics' median EPS (Basic) value was -$0.62 (recorded in 2024), while the average stood at -$0.68.
  • Within the past 5 years, the most significant YoY rise in Relay Therapeutics' EPS (Basic) was 7801.24% (2021), while the steepest drop was 17490.69% (2021).
  • Over the past 5 years, Relay Therapeutics' EPS (Basic) (Quarter) stood at -$0.62 in 2021, then grew by 11.29% to -$0.55 in 2022, then decreased by 21.82% to -$0.67 in 2023, then rose by 20.6% to -$0.53 in 2024, then increased by 19.17% to -$0.43 in 2025.
  • Its last three reported values are -$0.43 in Q3 2025, -$0.41 for Q2 2025, and -$0.46 during Q1 2025.